Trials / Recruiting
RecruitingNCT07255209
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 12 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \<18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo SA.QW |
| DRUG | IBI362 | IBI362 SA.QW |
Timeline
- Start date
- 2025-12-29
- Primary completion
- 2027-10-31
- Completion
- 2028-10-31
- First posted
- 2025-11-28
- Last updated
- 2026-01-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07255209. Inclusion in this directory is not an endorsement.